Daratumumab is an investigational anti-cancer drug. It binds to CD38. Daratumumab was originally developed by Genmab but it is now being jointly developed by Genmab along with the Johnson & Johnson subsidiary Janssen Biotech which acquired worldwide commercialization rights to the drug from Genmab.
This page contains content from the copyrighted Wikipedia article "Daratumumab"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.